Literature DB >> 17560273

Targeting of AID-mediated sequence diversification by cis-acting determinants.

Shu Yuan Yang1, David G Schatz.   

Abstract

After their assembly by V(D)J recombination, immunoglobulin (Ig) genes undergo somatic hypermutation, gene conversion, and class switch recombination to generate additional antibody diversity. The three diversification processes depend on activation-induced cytidine deaminase (AID) and are tightly linked to transcription. The reactions occur primarily on Ig genes and the molecular mechanisms that underlie their targeting to Ig loci have been of intense interest. In this chapter, we discuss the evidence linking transcription and transcriptional control elements to the three diversification pathways, and we consider how various features of chromatin could render parts of the genome permissive for AID-mediated sequence diversification.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17560273     DOI： 10.1016/S0065-2776(06)94004-8

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


  13 in total

1.  The RNA exosome targets the AID cytidine deaminase to both strands of transcribed duplex DNA substrates.

Authors:  Uttiya Basu; Fei-Long Meng; Celia Keim; Veronika Grinstein; Evangelos Pefanis; Jennifer Eccleston; Tingting Zhang; Darienne Myers; Caitlyn R Wasserman; Duane R Wesemann; Kurt Januszyk; Richard I Gregory; Haiteng Deng; Christopher D Lima; Frederick W Alt
Journal:  Cell       Date:  2011-01-20       Impact factor: 41.582

2.  Separation of mutational and transcriptional enhancers in Ig genes.

Authors:  Naga Rama Kothapalli; Kaitlin M Collura; Darrell D Norton; Sebastian D Fugmann
Journal:  J Immunol       Date:  2011-08-15       Impact factor: 5.422

3.  V-region mutation in vitro, in vivo, and in silico reveal the importance of the enzymatic properties of AID and the sequence environment.

Authors:  Thomas MacCarthy; Susan L Kalis; Sergio Roa; Phuong Pham; Myron F Goodman; Matthew D Scharff; Aviv Bergman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

4.  Binding of LBP-1a to specific immunoglobulin switch regions in vivo correlates with specific repression of class switch recombination.

Authors:  Karen J Repetny; Xuemei Zhong; Nichol E Holodick; Thomas L Rothstein; Ulla Hansen
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

Review 5.  A coming-of-age story: activation-induced cytidine deaminase turns 10.

Authors:  Rebecca K Delker; Sebastian D Fugmann; F Nina Papavasiliou
Journal:  Nat Immunol       Date:  2009-10-20       Impact factor: 25.606

6.  Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting.

Authors:  Ravi K Dinesh; Benjamin Barnhill; Anoj Ilanges; Lizhen Wu; Daniel A Michelson; Filip Senigl; Jukka Alinikula; Jeffrey Shabanowitz; Donald F Hunt; David G Schatz
Journal:  Eur J Immunol       Date:  2019-12-19       Impact factor: 5.532

7.  The splicing regulator PTBP2 interacts with the cytidine deaminase AID and promotes binding of AID to switch-region DNA.

Authors:  Urszula Nowak; Allysia J Matthews; Simin Zheng; Jayanta Chaudhuri
Journal:  Nat Immunol       Date:  2010-12-26       Impact factor: 25.606

8.  Classical Mus musculus Igκ enhancers support transcription but not high level somatic hypermutation from a V-lambda promoter in chicken DT40 cells.

Authors:  Naga Rama Kothapalli; Darrell D Norton; Sebastian D Fugmann
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

9.  Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes.

Authors:  Leng-Siew Yeap; Joyce K Hwang; Zhou Du; Robin M Meyers; Fei-Long Meng; Agnė Jakubauskaitė; Mengyuan Liu; Vinidhra Mani; Donna Neuberg; Thomas B Kepler; Jing H Wang; Frederick W Alt
Journal:  Cell       Date:  2015-11-12       Impact factor: 41.582

10.  Identification of core DNA elements that target somatic hypermutation.

Authors:  Kristin M Kohler; Jessica J McDonald; Jamie L Duke; Hiroshi Arakawa; Sally Tan; Steven H Kleinstein; Jean-Marie Buerstedde; David G Schatz
Journal:  J Immunol       Date:  2012-10-19       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.